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Abstract
Background: In the developing world co-infections and polyparasitism within humans appear to be the rule rather
than the exception, be it any combination of inter-specific and/or inter- and intra-Genera mixed infections. Mixed
infections might generate synergistic or antagonistic interactions and thereby clinically affect individuals and/or
impact parasite epidemiology.
Methods: The current study uniquely assesses both Schistosoma mansoni- and Schistosoma haematobium-related
morbidity of the liver and the bladder as assessed by ultrasound as well as spleen and liver morbidity through
clinical exams. The impact of praziquantel (PZQ) treatment on such potential inter-specific schistosome interactions
and resulting morbidity using uniquely detailed longitudinal data (pre- and one year post-PZQ treatment) arising
from the National Schistosomiasis Control Program in three areas of Mali: Ségou, Koulikoro and Bamako, is also
evaluated. At baseline, data were collected from up to 2196 children (aged 7-14 years), 844 of which were infected
with S. haematobium only, 124 with S. mansoni only and 477 with both. Follow-up data were collected from up to
1265 children.
Results: Results suggested lower liver morbidity in mixed compared to single S. mansoni infections and higher
bladder morbidity in mixed compared to single S. haematobium infections. Single S. haematobium or S. mansoni
infections were also associated with liver and spleen morbidity whilst only single S. haematobium infections were
associated with bladder morbidity in these children (light S. haematobium infection OR: 4.3, p < 0.001 and heavy
S. haematobium infection OR: 19, p < 0.001). PZQ treatment contributed to the regression of some of the forms of
such morbidities.
Conclusions: Whilst the precise biological mechanisms for these observations remain to be ascertained, the results
illustrate the importance of considering mixed species infections in any analyses of parasite-induced morbidity,
including that for the proposed Disability Adjusted Life Years (DALYs) revised estimates of schistosomiasis
morbidity.
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Background
In the developing world co-infections and polyparasit-
ism within humans appear to be the rule rather than
the exception. New integrated control programmes
acknowledge this, with for instance combined mass
drug administration (MDA) for schistosomiasis, lym-
phatic filariasis, onchocerciasis, trachoma and soil-
transmitted helminths being initiated throughout parts
of sub-Saharan Africa [1]. However, within-Genera
polyparasitism must also be fully acknowledged. More-
over, synergistic or antagonistic interactions resulting
from such co-infections may be predicted to clinically
affect individuals and/or impact parasite epidemiology
[2].
Schistosomiasis is a chronic and debilitating disease
which affects millions of people, particularly the rural
poor in the developing world. Of some 600 million peo-
ple at risk, an estimated 200 million are infected, more
than half of which are symptomatic and at least 20 mil-
lion exhibit severe disease manifestations [3]. Schisto-
somes, the causative agents, are parasitic bloodflukes
(Phylum: Platyhelminth; Class: Trematoda) with indir-
ectly transmitted life-cycles involving obligatory alterna-
tion of generations between sexual reproduction in a
mammalian host and asexual reproduction within a
molluscan (freshwater snail) host. The clinical manifes-
tations of schistosomiasis are classically associated with
the species-specific ovipositioning (egg-laying) sites; the
mesenteric venous systems for Schistosoma mansoni
(prevalent in sub-Saharan Africa and South America)
leading to chronic hepatic and intestinal fibrosis and the
vesical venous plexus of the urogenital system for Schis-
tosoma haematobium (prevalent in sub-Saharan Africa)
associated with ureteral and bladder fibrosis, calcifica-
tion of the urinary tract and bladder cancer [4].
Co-infections between S. mansoni and S. haemato-
bium have been reported in an increasing number of
foci across Africa [5-9]. Furthermore, studies in Camer-
oon and Senegal have revealed that in areas of overlap,
S. mansoni-shaped eggs may be excreted in urine as
opposed to the usual faecal route [10]. Studies on schis-
tosomiasis-associated morbidity tend to, nevertheless,
always consider single species infections individually [3].
In addition to affecting the prevalence and intensity of
human infections, inter-specific parasite interactions
during mixed species infections may, however, also be
predicted to impact host morbidity directly. In one of
the few studies to consider this, Cunin et al. (2003) in
Cameroon, for example, reported an apparent lowering
of S. mansoni-induced morbidity (hepatomegaly and
splenomegaly morbidity, as determined through clinical
palpation) in mixed infections with S. haematobium
relative to that observed for S. mansoni single infections
[6]. The authors suggested that this lowering effect on
liver morbidity could be due to S. haematobium males
mating with S. mansoni females (which cannot success-
fully hybridize) and the subsequent eggs produced from
such couplings passing to the urinary oviposition site,
thereby reducing the amount of classical S. mansoni-
induced morbidity. Laboratory rodent model studies
have confirmed these observations [11].
Preventive mass drug administration (MDA) interven-
tions, as are recently being employed across parts of
sub-Saharan Africa [12,13], may be further predicted to
have an impact on such complex inter-specific interac-
tions, especially if the selection pressure differs between
the parasite species, as may be plausible for S. mansoni
and S. haematobium [14]. For example, S. mansoni and
S. haematobium differ in their generation times/length
of time to maturation, and as juvenile schistosomes are
not susceptible to PZQ, this could potentially lead to
differences between these two species in terms of their
responses to MDA within individual hosts. Such differ-
ences could also subsequently affect the order of estab-
lishment of the parasites within their human hosts (a
factor known to be very important in determining the
outcome of inter-specific competition and subsequent
parasite-induced host morbidity [15,9]).
However, despite the theoretical and applied interest
of mixed schistosome species interactions on human
host morbidity under differing selective pressures, few
studies appear to have focused upon this. Indeed, to the
authors knowledge, no studies have yet examined the
potential consequence of S. haematobium-associated
bladder pathology in mixed species infections, nor the
potential impact of MDA on hepatic and urinary-asso-
ciated morbidity of mixed schistosome species
infections.
The aim of the current study was to test if the
hypothesis that liver morbidity in mixed schistosome
species infections is lower relative to that observed for
S. mansoni single infections [6], can be generalized in
different environmental settings within sub-Saharan
Africa such as Mali. Furthermore, while previous studies
were restricted to clinical examination and palpation of
hepatomegaly and splenomegaly, the present study also
incorporates detailed ultrasonography (US) to determine
schistosome-specific morbidity in the liver and bladder.
Finally, the current study also evaluates the impact of
PZQ treatment on such potential inter-specific schisto-
some interactions and resulting morbidity using
uniquely detailed longitudinal data (pre- and one year
post-praziquantel (PZQ) treatment) arising from
the National Schistosomiasis Control Program in three
areas of Mali: Ségou, Koulikoro and Bamako. The
results obtained should have theoretical and applied
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implications regarding inter-specific schistosome inter-
actions and human morbidity.
Methods
Study design
The schools included in these surveys were randomly
selected from all schools known a priori to be places
where schistosomiasis is highly endemic: Ségou, Bamako
and Koulikoro. Details concerning sample-size calcula-
tions and cohort design have been described elsewhere
[16]. We would like to acknowledge that this study
describes data from an ongoing MDA control pro-
gramme and not a double-blind placebo randomized
clinical trial study.
Initially 2196 children (aged 7 to 14 years) from 29
schools were recruited with US and parasitological data
on both schistosome species infections. Of these, 844
children were infected with S. haematobium only, 124
with S. mansoni only and 477 with both. Clinical exami-
nations (i.e. liver and spleen palpations) were performed
on 2128 of these children, as part of the baseline survey
(of these, 821 children were infected with S. haemato-
bium only, 117 with S. mansoni only and 463 with
both).
Only 23 of the 29 schools surveyed at baseline were
visited at the second survey, due to financial and time
constraints. All subsequent analyses here of the follow-
up (second survey) data exclude baseline data from the
6 schools that were not followed up. Follow-up data
were collected from 1265 children from 23 schools (76%
of the 1670 children recruited from these schools at
baseline) but only 853 children had complete clinical,
US and parasitological data on both schistosomiasis
infections. Follow-up rates following the first survey
were much higher for children under 13 years of age, as
is common in such sub-Saharan regions where primary
school children leave for reasons such as work or early
marriage [17].
Baseline surveys took place in the Ségou area in
March and April of 2004 while the follow-up surveys
were performed just over one year later (i.e. in May
2005). By the second survey children in the schools of
this area had received two MDA treatments with PZQ:
a) one just after baseline data collection (in March-April
2004) and b) another during preventive chemotherapy
intervention (in February 2005). In Bamako baseline sur-
veys took place in July 2004 while the majority of the
follow-up surveys were performed almost two years
later (i.e. in April-May 2006) with the remaining three
schools in this area to be visited in October 2006. A sin-
gle round of MDA took place in 2005 (i.e. in May, June
and November). Finally baseline surveys took place in
Koulikoro during June-August 2004 while the follow-up
surveys took place almost two years later (i.e. in May
2006). The children would have received one PZQ treat-
ment during the MDA in August 2005.
Clinical, ultrasound and parasitological examination
Clinical examination was performed on each child by
experienced clinical nurses who were blind to parasito-
logical results. The following measurements were
recorded: the excursion in centimeters of the spleen
below the rib cage in the left mid-clavicular line (MCL)
and left mid-axillary line (MAL); liver tenderness; the
excursion in centimeters of the left liver lobe beneath
the sternum in the mid-sternal line (MSL); the excur-
sion of the right liver lobe beneath the rib cage in the
right MCL. The consistency of the liver and spleen were
also graded as follows: not palpable, soft, firm and hard.
The presence of physical abnormalities such as ascites
or other abdominal swelling, umbilical collaterals and
scars were recorded as being present or absent, and
finally, the presence of liver tenderness or febrility were
noted [18].
Ultrasound (US) examination was performed with a
portable ultrasonography device (SSD-500; Aloca,
Tokyo, Japan). For parasitologic examinations, a filtra-
tion method was used to determine S. haematobium
infection intensity, whilst the Kato-Katz (KK) technique
was employed to define S. mansoni infection intensity.
Further details have been described elsewhere for both
US and KK [16].
Ethics statement
Ethical approval was obtained from the St Mary’s Hospi-
tal Local Ethics Research Committee, R&D office (part
of the Imperial College, London Research Ethics Com-
mittee (ICREC)) in combination with the ongoing Schis-
tosomiasis Control Initiative (SCI) activities, in areas
where SCI is physically based. Within Mali, all aspects
of Monitoring and Evaluation were carried out in the
framework of the disease control activities implemented
and approved by the Ministry of Health (MOH) and
adopted by regional and local administrative and health
authorities. The communities of the selected villages
were informed about the objectives, the methodology of
the study and the advantages. A meeting was organized
with the population and verbal community consent was
obtained for each selected village. Where the study was
performed within the schools, verbal consent was also
obtained from school teacher’s directors and teachers,
prior to the recruitment of the children. Within Mali,
for cultural reasons, obtaining verbal consent from the
community leaders/heads of villages (via community
forum), and teachers’ directors, is the most accepted
procedure, and hence the practice we followed here.
The results of the different diagnostic procedures per-
formed on children were briefly explained to the
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children themselves. If any pathology was discovered,
this was reported to the parents or guardians, or, if this
was not possible, carefully explained to the teachers for
them to brief the children’s parents or guardians. The
health officer responsible for the nearest medical post,
who was usually present on spot at the time of the
examinations, was also informed about the pathology of
the children and asked to take care of them, according
to the practices and procedures of the national health
system of Mali.
Statistical Analyses
Baseline (pre-MDA) data were used to investigate
whether or not there was an association between schis-
tosomiasis infection status and pathological manifesta-
tions as determined by US examinations for liver and
bladder morbidity as well as by clinical examinations for
liver and spleen morbidities. Univariate analyses were
performed using chi-square tests for associations
between schistosomiasis infection status and the various
pathological manifestations.
In order to study simultaneously the impact of several
covariates on the pathological manifestations at baseline,
logistic regression models with random effects at the
school level (i.e. multilevel logistic regressions) were
fitted using the PROC NLMIXED command in SAS ver-
sion 9.1 (SAS Institute Inc., Cary, NC). Schistosomiasis
infections were classified on the basis of intensities
using WHO standards (see S1a in Additional file 1), and
these intensity classes were included as covariates. The
assumption of linear effects of age was tested through
comparison with models including categorical effects for
each year of age. The assumption of linear effects of
infection intensity classes was tested using the Akaike
information criterion (AIC) to compare models assum-
ing linear effects (with and without an interaction of
those linear effects) with models fitting separate effects
for each combination of S. mansoni and S. haemato-
bium intensity classes. The intensity classes for S. hae-
matobium infection were assigned 0 for ‘not infected’
(0e/10 ml), 1 for ‘light’ (< 50e/10 ml) and 2 for ‘heavy’
(> 50e/10 ml) while the intensity classes for S. mansoni
infection were assigned 0 for ‘not infected’ (0 epg), 1 for
‘light’ (1-99 epg), 2 for ‘medium’ (100-399 epg) and 3
for ‘heavy’ (> 400 epg).
Differences in baseline characteristics were tested
between children successfully and unsuccessfully fol-
lowed up by univariate analysis using a Wilcoxon 2-
sample test for means and a chi-square test or Fisher’s
exact test if there were small values for proportions.
The data were further analyzed excluding data from 13-
and 14-year-old children because children in these age
groups would be more likely to have left school during
interval between baseline and follow-up assessments.
Statistical analysis for the effect of MDA (i.e. post
PZQ treatment, one year follow-up) was restricted to
children with complete records on all outcomes of inter-
est here (i.e. parasitological, US and clinical exam data)
from both baseline and follow-up surveys. Differences in
baseline and separately follow-up health characteristics
of children between pairs of the three surveyed areas of
the country were performed using two-proportion
z-tests of unequal variances. Such comparisons were
performed as different treatment strategies had been fol-
lowed between these regions.
Changes of the health characteristics of children
between the two time points of the study in relation to
their baseline schistosomiasis infection status, adjusting
at the same time for age and sex, were analyzed using
generalized logit multinomial models for all three areas
and for each morbidity measure using the PROC
LOGISTIC command in SAS version 9.1 (SAS Institute
Inc., Cary, NC). In these models schistosome infection
status was characterized as simply infected or not
infected, rather than by the intensity of infection, based
on model fits with prevalence and linear effects of inten-
sity (see S3 in Additional File 1 for further details).
Finally, in these models the response variable was a
new categorical variable with four levels indicating the
following: a) no pathological manifestation of each mor-
bidity measure at both time points, b) pathological man-
ifestation of each morbidity measure at baseline but
cured at final point of the study, c) no pathological
manifestation of each morbidity measure at baseline and
pathological manifestation of each morbidity measure at
final point of the study, or d) pathological manifestation
of each morbidity measure at both time points.
Results
The ages of children were found to be approximately
matched between infection status groups. The mean
ages were: for the uninfected children 10.13 years old;
for the children with single S. haematobium infection
10.52 years old; for the children with single S. mansoni
infection 10.96 years old; for those children who were
co-infected with both schistosomes species the mean
age was 10.64 years old.
Univariate analysis for the association between
schistosomiasis infection status and pathological
manifestations at baseline
Figure 1 presents baseline prevalence levels of liver or
spleen morbidity as determined by US or clinical exami-
nations and bladder morbidity as determined by US
examination for those with single and both schistosome
species infections as well as those who were uninfected.
Chi-square tests revealed that the prevalence of liver
and spleen morbidity (pathology characteristics 1 to 7 in
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Figure 1) did not differ significantly in children with
S. mansoni infection only compared with co-infected
children. Similarly, the bladder morbidity (pathology
characteristic 8, in Figure 1) did not differ significantly
in children with S. haematobium infection only com-
pared with co-infected children.
However, the prevalence levels of liver morbidity in
the forms of portal hypertension and hepatomegaly, as
assessed both by US, were significantly higher among
children infected with S. haematobium only than among
uninfected children (p = 0.017 & p = 0.002 respectively
for pathology characteristics 2 and 3 in Figure 1). Simi-
larly, clinical examination revealed significantly higher
prevalence levels of liver morbidity among children
infected with S. haematobium only than among unin-
fected children (p = 0.001 and p = 0.010 respectively for
pathology characteristics with numbers 4 and 5 in
Figure 1).
Clinical examination revealed significantly higher pre-
valence levels of spleen morbidity among children
infected with S. haematobium only than among unin-
fected children (p < 0.001 for both pathology character-
istics 6 and 7 in Figure 1). Finally, the prevalence level
of bladder morbidity was significantly higher among
children infected with S. haematobium only than among
uninfected children (p < 0.001 for pathology characteris-
tic 8 in Figure 1).
Multivariate analyses for the association between the
intensity of schistosomiasis infection status and
pathological manifestations at baseline
Models with linear effects of intensities yielded better fit
through AIC comparisons and these are the results that
are presented here (see S1b in Additional File 1). The
adjusted odds ratios (ORs) for gender and age from
multilevel multivariate logistic regression models for the
Figure 1 Univariate analysis for association between single and mixed schistosomiasis infections with liver, bladder and spleen
pathology as assessed by US and clinical examination at baseline (n = 2128 children). Numerical coding for pathology characteristics in
the horizontal axis of Figure 1 represent the following: 1: Abnormal liver image patterns as assessed by US examination; 2: Portal Hypertension
(as determined by positive PVD scores from US examination); 3: Hepatomegaly as determined by positive PSL scores from US examination; 4:
Hepatomegaly as determined by MSL>2 cm from clinical examination; 5: Hepatomegaly as determined by MCL>2 cm from clinical examination;
6: Splenomegaly as determined by MCL>2 cm from clinical examination; 7: Splenomegaly as determined by MAL>2 cm from clinical
examination; 8: Bladder pathology (as determined by positive global scores from US examination). US, ultrasound; PVD, portal vein diameters:
PSL, parasternal line; MSL, mid-sternal line; MCL, mid-clavicluar line; MAL, mid-axillary line.
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liver pathology outcomes, as assessed by US examina-
tion, are shown in Table 1. Estimates for the risk of hav-
ing an abnormal liver image pattern indicated that
children infected with S. mansoni only (light, medium
and heavy intensities) were significantly more likely to
have an abnormal liver image pattern compared to
uninfected children (OR: 1.6, p = 0.008; OR: 2.5, p =
0.008 and OR:3.9, p = 0.008 respectively), while the data
indicated that co-infected children were at lower risk of
liver morbidity, in the form of an abnormal liver image
pattern, than children with single S. mansoni species
infections of the same intensity. Furthermore, there
Table 1 Multivariate logistic regressions for liver pathology as assessed by US examination at baseline (n = 2128)
Estimates from multilevel logistic regressions for liver pathology as assessed by US
Adjusted ORs for gender and age (95% CI) and p-values for the risk of having
abnormal liver image pattern
Type of schistosomiasis infection intensity related variables For S. mansoni
For S. haematobium none light medium heavy
none 1 1.569 2.463 3.866
(1.123 to 2.194) (1.261 to 4.812) (1.416 to 10.556)
p = 0.008 p = 0.008 p = 0.008
Light 0.526 0.825 1.295 2.033
(0.343 to 0.807) (0.520 to 1.309) (0.654 to 2.565) (0.769 to 5.374)
p = 0.003 p = 0.415 p = 0.458 p = 0.153
Heavy 0.277 0.434 0.681 1.069
(0.117 to 0.651) (0.190 to 0.990) (0.271 to 1.715) (0.350 to 3.267)
p = 0.003 p = 0.047 p = 0.415 p = 0.907
Adjusted ORs for gender and age (95% CI) and p-values for the risk of having
portal hypertension as assessed by positive PVD scores
For S. mansoni
For S. haematobium none light medium heavy
None 1 0.882 0.778 0.686
(0.655 to 1.187) (0.429 to 1.410) (0.281 to 1.674)
p = 0.408 p = 0.408 p = 0.408
Light 1.013 0.893 0.788 0.695
(0.698 to 1.470) (0.582 to 1.372) (0.417 to 1.489) (0.284 to 1.703)
p = 0.946 p = 0.606 p = 0.463 p = 0.426
Heavy 1.026 0.905 0.798 0.704
(0.487 to 2.161) (0.429 to 1.908) (0.339 to 1.881) (0.248 to 2.000)
p = 0.946 p = 0.793 p = 0.606 p = 0.510
Adjusted ORs for gender and age (95% CI) and p-values for the risk of having
of hepatomegaly as assessed by positive PSL scores
For S. mansoni
For S. haematobium none light medium heavy
None 1 4.583 21.006 96.274
(1.517 to 13.844) (2.301 to 191.788) (3.490 to 2656.018)
p = 0.007 p = 0.007 p = 0.007
Light 3.409 4.705 6.494 8.964
(1.273 to 9.125) (1.201 to 18.425) (0.777 to 54.292 (0.453 to 177.253)
p = 0.015 p = 0.026 p = 0.084 p = 0.150
Heavy 11.619 4.83 2.008 0.835
(1.621 to 83.261) (0.536 to 43.480) (0.077 to 52.677) (0.008 to 85.355)
p = 0.015 p = 0.160 p = 0.676 p = 0.939
The categories for the intensity of S. haematobium infection were defined according to WHO guidelines as: none: 0 e/10 ml; light: < 50 e/10 ml and heavy: ≥ 50
e 10 ml.
The categories for the intensity of S. mansoni infection were defined according to WHO guidelines as: none: 0 epg; light: 1-99 epg; moderate: 100-399 epg; and
heavy: ≥ 400 epg
e/10 ml, eggs/10 milliliters & epg, eggs per gram
These categorizations for both schistosomes species apply for all tables presented beyond this point.
ORs, Odds Ratios; 95% CIs, 95% Confidence Intervals
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were no significantly increased risks of liver morbidity,
in the form of an abnormal liver image pattern, among
the co-infected children than among the uninfected chil-
dren. Children infected with S. haematobium only (both
light and heavy intensities) were significantly less likely
to have an abnormal liver image pattern compared to
uninfected children (OR: 0.5, p = 0.003 and OR: 0.3, p =
0.003 respectively).
As regards the risk of having portal hypertension,
the multilevel multivariate logistic regression model
(Table 1) did not yield any significant associations with any
of the intensities of the single or mixed schistosome
species.
Regarding the risk of having hepatomegaly as assessed
by positive PSL scores, children with single infections (S.
mansoni only or S. haematobium only) were more likely
to have this marker of liver morbidity than uninfected
children (with children with medium and heavy intensity
S. mansoni infections only being at particularly high risk:
OR: 21, p = 0.007 and OR = 96, p = 0.007, respectively).
The data indicated that children with medium and high
intensity S. mansoni infections, but no S. haematobium
infection, were at substantially higher risk of liver morbid-
ity of this form than co-infected children with medium
and high intensity S. mansoni infections. Furthermore,
there were no significantly increased risks of liver morbid-
ity, as assessed by positive PSL scores, among the co-
infected children with medium and high intensity S. man-
soni infections than among the uninfected children.
The risk of having hepatomegaly as assessed by
MSL>2 cm (Table 2) appeared to depend only upon the
intensity of the S. mansoni infection (risk was lowest
with no infection and increased with increased S. man-
soni intensity), with no effect of any S. haematobium
infection. Similarly, the risk of having hepatomegaly as
assessed by MCL>2 cm (Table 2) appeared to depend
only upon the intensity of the S. mansoni infection (risk
was lowest with no infection and increased with
increased S. mansoni intensity), with no effect of any S.
haematobium infection.
The risk of having splenomegaly as assessed once by
MCL>2 cm and then by MAL>2 cm did not depend on
the presence, or intensity of single or mixed S. mansoni
infection but it was slightly reduced in the presence of
single S. haematobium infection (Table 2).
The risk of bladder pathology as assessed by US exam-
ination (Table 3) did not depend on the presence, or
intensity of single S. mansoni infection but was much
increased in the presence of single S. haematobium
infection (light S. haematobium infection OR: 4.3, p <
0.001 and heavy S. haematobium infection OR: 19, p <
0.001 for children uninfected with S. mansoni in both
cohorts) and even further in the presence of mixed
infections.
Drop out rates at follow-up
There were significant differences in the ages of the 853
children successfully followed up and the 817 children
who dropped out during the follow-up (p < 0.001); chil-
dren who dropped out were older on average than chil-
dren who were successfully followed up (i.e. 11.25 years
versus 9.62 years). There were also significant differ-
ences between these two groups of children with refer-
ence to the prevalence of abnormal liver image patterns
(p = 0.024) and the bladder pathology (p = 0.010), as
determined by US examination, as well as the preva-
lence of hepatomegaly and splenomegaly as determined
by clinical examination (p = 0.020 and p = 0.003 respec-
tively). These indicators of morbidity were significantly
lower at baseline among children that dropped out than
in children who were successfully followed up. For all
other pathological manifestations considered, there were
no significant differences between these two groups of
children: those who dropped out and those who were
successfully followed up.
Excluding data from children aged 13 and 14 years at
baseline, the only significant follow-up differences were
that the prevalences of mixed schistosome species infec-
tions and bladder pathology were significantly lower in
those children who dropped out compared to those who
were successfully followed up. The observation that
most features examined were similar in children that
were successfully followed up and children who dropped
out during the follow-up suggested that results obtained,
after appropriate adjustment for age, were largely repre-
sentative of the population from which the sample had
been selected (see S2 in Additional File 1 for further
details).
Impact of MDA
Both at baseline and at follow-up the heaviest intensities
of S. haematobium infection were observed in Ségou
while the heaviest intensities of S. mansoni infection
were observed in Koulikoro (Table 4). However, in all
three areas and for both schistosome species, there were
observed significant decreases from baseline to follow-
up in the classes of heavy intensities with the exception
of Bamako area and the heavy intensity of S. mansoni
infection. It should be noted though that the latter was
very low at baseline and thus even if there was a signifi-
cant drop post treatment, it was unlikely to have been
detected with this small sample size. Co-infections also
decreased significantly in all three areas at follow-up
relative to baseline.
There were no substantial changes in the prevalence
of abnormal liver image patterns from baseline to fol-
low-up in all three areas (Table 4). Only hepatomegaly
in Ségou was observed to decrease significantly from
baseline to follow-up. Likewise, the prevalence of
Koukounari et al. BMC Infectious Diseases 2010, 10:227
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Table 2 Multivariate logistic regressions for liver and spleen pathology as assessed by clinical examination at baseline
(n = 2128)
Estimates from multilevel logistic regressions
Adjusted ORs for gender and age (95% CI) and p-values for the risk of having
hepatomegaly as assessed by MSL >2 cm
Type of schistosomiasis infection intensity related variables For S. mansoni
For S. haematobium none light medium heavy
None 1 1.431 2.049 2.932
(1.008 to 2.033) (1.016 to 4.132) (1.024 to 8.399)
p = 0.045 p = 0.045 p = 0.045
Light 0.995 1.425 2.039 2.919
(0.614 to 1.612) (0.839 to 2.419) (0.956 to 4.349) (1.016 to 8.383)
p = 0.985 p = 0.190 p = 0.065 p = 0.047
Heavy 0.991 1.418 2.03 2.905
(0.377 to 2.600) (0.548 to 3.667) (0.704 to 5.850) (0.825 to 10.230)
p = 0.985 p = 0.471 p = 0.190 p = 0.097
Adjusted ORs for gender and age (95% CI) and p-values for the risk of having
hepatomegaly as assessed by MCL>2 cm
For S. mansoni
For S. haematobium none light medium heavy
None 1 1.446 2.092 3.025
(1.006 to 2.078) (1.013 to 4.320) (1.019 to 8.979)
p = 0.046 p = 0.046 p = 0.046
Light 1.057 1.529 2.211 3.198
(0.652 to 1.713) (0.895 to 2.611) (1.017 to 4.805) (1.078 to 9.484)
p = 0.822 p = 0.120 p = 0.045 p = 0.036
Heavy 1.117 1.616 2.337 3.38
(0.425 to 2.934) (0.623 to 4.189) (0.801 to 6.815) (0.937 to 12.196)
p = 0.822 p = 0.323 p = 0.120 p = 0.063
Adjusted ORs for gender and age (95% CI) and p-values for the risk of having
splenomegaly as assessed by MCL>2 cm
For S. mansoni
For S. haematobium none light medium heavy
None 1 1.068 1.142 1.22
(0.864 to 1.321) (0.747 to 1.745) (0.645 to 2.306)
p = 0.541 p = 0.541 p = 0.541
Light 0.768 0.82 0.876 0.936
(0.594 to 0.992) (0.607 to 1.108) (0.557 to 1.378) (0.494 to 1.776)
p = 0.044 p = 0.197 p = 0.568 p = 0.840
Heavy 0.589 0.629 0.673 0.719
(0.352 to 0.985) (0.375 to 1.057) (0.368 to 1.228) (0.343 to 1.505)
p = 0.044 p = 0.080 p = 0.197 p = 0.381
Adjusted ORs for gender and age (95% CI) and p-values for the risk of having
splenomegaly as assessed by MAL>2 cm
For S. mansoni
For S. haematobium none light medium heavy
None 1 1.099 1.207 1.326
(0.879 to 1.373) (0.773 to 1.886) (0.679 to 2.591)
p = 0.408 p = 0.408 p = 0.408
Light 0.754 0.829 0.911 1.001
(0.576 to 0.988) (0.604 to 1.139) (0.565 to 1.468) (0.510 to 1.965)
p = 0.041 p = 0.247 p = 0.701 p = 0.998
heavy 0.569 0.625 0.687 0.755
(0.332 to 0.977) (0.362 to 1.079) (0.364 to 1.296) (0.346 to 1.646)
p = 0.041 p = 0.092 p = 0.247 p = 0.480
ORs, Odds Ratios; 95% CIs, 95% Confidence Intervals
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bladder pathology decreased significantly only in Ségou
at follow-up relative to baseline. In the other two areas,
follow-up results indicated significant increases relative
to baseline. Within both time points, differences in
these proportions were statistically significant when
comparing Ségou with the other two areas (Table 4).
Results of clinical examinations suggested significant
decreases in the prevalence of splenomegaly in Kouli-
koro and Ségou from baseline to follow-up. The preva-
lence of splenomegaly in Bamako between the two time
points of the study was similar. For the prevalence of
hepatomegaly, there was a significant decrease between
the two time points of the study only in Ségou whilst in
the other two surveyed areas this was similar.
As the descriptive analysis of the results of clinical and
US examinations indicated very low prevalences of
pathology in Bamako and Koulikoro, the fitting of multi-
nomial models for the changes of pathological manifes-
tations was restricted to the data of children from
Ségou. Even within the Ségou area, the fitting algorithm
converged only for four outcome variables: liver image
patterns, portal hypertension as determined by positive
PVD scores from US examination, splenomegaly as
assessed by MCL exceeding 2 cm from clinical examina-
tion and splenomegaly as assessed by MAL exceeding
2 cm from clinical examination (see Table 5 for results).
In addition valid results were obtained only when the
schistosome infection status was characterized as simply
infected or not infected (see S3 in Additional File 1 for
further details).
Considering liver image patterns, children with S.
mansoni infection at baseline compared to those without
were more likely to have liver image pathology at one or
both time points. In addition, among those children
with liver pathology at baseline, those with S. mansoni
infection at baseline were much more likely than
children without to have liver pathology at follow-up
(OR for pathology at both time points: 34.6 was much
greater than OR for pathology at baseline but no pathol-
ogy at follow-up: 3.1).
The regression model for portal hypertension from US
showed that children with S. mansoni infection at base-
line would have such pathology at baseline but it did
not enable us to predict what is going to happen after
treatment (OR for pathology at both time points: 2.8
was similar to the OR for pathology at baseline but not
at follow-up: 3.1).
Children with S. mansoni infection at baseline com-
pared to those with no S. mansoni infection were most
likely to have splenomegaly as assessed by clinical exam-
ination at both examined time points of interest (OR =
2.9, p = 0.002).
Finally, those children infected with S. haematobium
at baseline proved significantly less likely than those
without S. haematobium to have liver pathology at both
time points of study (OR = 0.2, p = 0.015; OR = 0.4, p
= 0.046 for the risk of portal hypertension and spleno-
megaly, respectively); those children infected with S.
haematobium at baseline proved also significantly less
likely than those without S. haematobium to have liver
pathology at baseline and being cured from such mor-
bidity at follow up.
Discussion
Both S. mansoni and S. haematobium schistosome spe-
cies infections are prevalent in much of sub-Saharan
Africa and are known to be co-endemic in several coun-
tries, such as Mali under study here, with currently
available studies contributing useful information with
regards to the epidemiology and immunology of each of
these separate specific parasitic infections [19-27]. In
contrast, however, very little is yet known about
Table 3 Multivariate logistic regression of bladder pathology as assessed by US at baseline (n = 2128)
Estimates from multilevel logistic regressions
Adjusted ORs for gender and age (95% CI) and p-values for the risk of having
bladder pathology as assessed by positive global scores
Type of schistosomiasis infectionintensity related variables For S. mansoni
For S. haematobium none light medium heavy
None 1 1.166 1.36 1.587
(0.923 to 1.473) (0.853 to 2.170) (0.787 to 3.198)
p = 0.197 p = 0.197 p = 0.197
Light 4.347 5.07 5.914 6.898
(3.232 to 5.847) (3.560 to 7.220) (3.513 to 9.955) (3.339 to 14.251)
p < 0.001 p < 0.001 p < 0.001 p < 0.001
Heavy 18.897 22.041 25.708 29.985
(10.446 to 34.186) (11.986 to 40.531) (12.677 to 52.134) (12.702 to 70.783)
p < 0.001 p < 0.001 p < 0.001 p < 0.001
ORs, Odds Ratios; 95% CIs, 95% Confidence Intervals
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potential interactions of concurrent infections, nor as
the associated clinical impact of mixed schistosome
infections on the human host. Further understanding of
polyparasitic interactions is essential in order to guide
public health measures in endemic areas [28]. To our
knowledge, our study represents the first which uses not
only clinical examination but also precise and detailed
ultrasonography in order to examine the impact of sin-
gle versus mixed schistosome species infections on
human hosts’ liver, spleen and bladder morbidity at the
same time, both pre- and post-chemotherapy.
We have demonstrated here that, in general, the risk
for baseline liver morbidity amongst these 7-14 year old
children, in the form of an abnormal liver image pattern
and hepatomegaly, as assessed by positive PSL scores,
was lower for co-infections if compared to single
S. mansoni infections of the same intensity. This finding
from Mali agrees with previous results of decreased
hepatomegaly, as determined by palpation, in co-infec-
tions from Cameroon [6]. Furthermore, our study has
also indicated through univariate analysis that at base-
line significantly more children with S. haematobium
only, compared to uninfected children, had liver mor-
bidity (i.e. portal hypertension and hepatomegaly-as
assessed by both US and clinical examination) or spleen
morbidity as assessed by clinical examination; baseline
results from multivariate analysis yielded significant
increased risks of hepatomegaly as assessed by positive
PSL scores for children with single S. haematobium
infections compared to uninfected children (ORs for
Table 4 Health characteristics of schoolchildren successfully retraced (i.e. pre and post treatment-n = 853)
Baseline Post-treatment
Bamako Koulikoro Ségou Bamako Koulikoro Ségou
(n = 273) (n = 153) (n = 427) (n = 273) (n = 153) (n = 427)
Parasitology
% Uninfected 45.05 (< 0.001)a 14.38 (< 0.001)b 8.90 (< 0.001)c 64.10 (< 0.001)d ** 32.68 (0.010)e ** 40.05 (< 0.001)f **
% Infected with
S. haematobium
43.96 (< 0.001)a 3.92 (< 0.001)b 57.38 (< 0.001)c 26.37 (< 0.001)d ** 5.23 (< 0.001)e 35.36 (0.011) f **
% Infected with S. mansoni 1.10 (< 0.001)a 24.84 (< 0.001)b 4.22 (0.007)c 4.03 (< 0.001)d ** 40.52 (< 0.001)e ** 14.05 (< 0.001)f **
% Co-infected 9.89 (< 0.001)a 56.86 (< 0.001)b 29.51 (< 0.001)c 5.49 (< 0.001)d ** 21.57 (0.002)e ** 10.54 (0.013)f **
% Heavy S. haematobium
infections
13.19 (0.040) a 7.19 (< 0.001) b 39.58 (< 0.001) 2.20 (0.161)c ** 0.65 (< 0.001) e ** 7.73 (< 0.001) f **
% Heavy S. mansoni infections 0.73 (< 0.001) 22.88 (0.005) 12.41 (< 0.001) 0.00 (< 0.001) 10.46 (0.003) ** 2.81 (< 0.001) **
Liver Pathology as assessed by ultrasound (US) examination
% with abnormal liver image
patterns
0.37 (0.316)a 0.00 (< 0.001)b 12.18 (< 0.001)c 0.37 (0.316)d 0.00 (< 0.001)e 12.88 (< 0.001)f
% with portal hypertension
(as determined by positive PVD
scores)
0.73 (0.585)a 1.31 (< 0.001)b 9.60 (< 0.001)c 5.49 (0.013)d ** 13.07 (0.076)e ** 7.73 (0.237)f
% with hepatomegaly (as
determined by positive PSL
scores from US)
0.37 (0.701)a 0.65 (0.085)b 2.34 (0.085)c 0.00 (0.316)d 0.65 (0.545)e 0.23 (0.317)f **
Liver + spleen pathology as assessed by clinical examination
% with hepatomegaly as
assessed by MSL>2 cm
0.00 (0.316)a 0.65 (< 0.001)b 9.84 (< 0.001)c 0.00 (0.080)d 1.96 (0.291)e 0.70 (0.082)f **
% with hepatomegaly as
assessed by MCL>2 cm
0.00 (0.316)a 0.65 (< 0.001)b 8.67 (< 0.001)c 0.00 (0.080)d 1.96 (0.291)e 0.70 (0.082)f **
% with splenomegaly as
assessed by MCL>2 cm
0.73 (< 0.001)a 12.42 (< 0.001)b 27.17 (< 0.001)c 0.00 (0.023)d 3.27 (0.009)e ** 8.43 (< 0.001)f **
% with splenomegaly as
assessed by MAL>2 cm
0.73 (< 0.001)a 8.50 (< 0.001)b 25.06 (< 0.001)c 0.00 (0.043)d 2.61 (0.010)e ** 7.26 (< 0.001)f **
Bladder Pathology as assessed by US examination
Bladder pathology (as
determined by positive global
scores from US)
8.42 (0.194)a 5.23 (< 0.001)b 22.95 (< 0.001)c 22.34 (0.057)d ** 15.03 (< 0.001)e ** 3.98 (< 0.001)f **
ap-values comparing proportions reported between Bamako and Koulikoro at baseline in parentheses; b p-values comparing proportions reported between
Koulikoro and Ségou at baseline in parentheses; c p-values comparing proportions reported between Bamako and Ségou at baseline in parentheses; d p-values
comparing proportions reported between Bamako and Koulikoro at follow-up in parentheses; e p-values comparing proportions reported between Koulikoro and
Ségou at follow-up in parentheses; f p-values comparing proportions reported between Bamako and Ségou at follow-up in parentheses; ** significant differences
at a = 0.05 between baseline and post treatment paired proportions as indicated by McNemar’s test
US, ultrasound; PVD, portal vain diameters; PSL, parasternal line; MSL, mid-sternal line; MCL, mid-clavicular line; MAL, mid-axillary line
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light and heavy intensities of S. haematobium infection
were estimated respectively as 3.4 and 11.6 in Table 1).
Such findings suggest that urinary schistosomiasis alone
might also lead to liver and spleen abnormalities, and
hence, where possible, potential liver morbidity para-
meters in S. haematobium infections should also be
examined during MDA monitoring and evaluation [29].
Indeed, to our knowledge, with the exception of com-
munity and hospital surveys performed in Egypt [30,31],
there are very few studies that have examined human
liver morbidity by US and clinical examinations in S.
haematobium infection, and our results here may imply
that such findings should also be taken into account in
the revised assessments of schistosomiasis morbidity
and disability adjusted life years (DALYS) [3].
The precise causation of such S. haematobium-asso-
ciated liver and spleen morbidity here remains, however,
unclear. One could speculate that children with single S.
Table 5 Multivariate multinomial logistic regressions for the changes of liver image patterns for Ségou area (n = 427)
Estimates from multinomial model with dependent variable indicating the change of liver image patterns during the 2 time points of the
study
(Adjusted ORs for gender and age, 95% CIs & p-values)
Dependent variable: the
risk of having pathology
at both time points
Dependent variable: the risk of having
no pathology at baseline and having
pathology at final point of the study
Dependent variable: the risk of
having pathology at baseline but
cured at final point of the study
Risk factors-Independent
variables at baseline(Reference
category)
Type of schistosomiasis
infection related variables at
baseline
Infected with S. haematobium
(Not infected with S.
haematobium)
0.353 (0.080 to 1.560)
p = 0.1691
2.339 (0.525 to 10.423) p = 0.2651 0.245 (0.110 to 0.544) p < 0.0011
Infected with S. mansoni (Not
infected with S. mansoni)
34.591 (4.315 to 277.268)
p < 0.0011
7.139 (3.513 to 14.506) p < 0.0011 3.081 (1.514 to 6.267) p = 0.0021
Estimates from model with dependent variable indicating the change of portal hypertension from ultrasound during the 2 time points of
the study
Type of schistosomiasis
infection related variables at
baseline
Infected with S. haematobium
(Not infected with
S. haematobium)
0.157 (0.036 to 0.695)
p = 0.0151
1.541 (0.346 to 6.865) p = 0.5711 0.612 (0.230 to 1.631) p = 0.3271
Infected with S. mansoni (Not
infected with S. mansoni)
2.792 (0.611 to 12.753)
p = 0.1851
0.188 (0.043 to 0.813) p = 0.0251 3.076 (1.460 to 6.482) p = 0.0031
Estimates from model with dependent variable indicating the change of splenomegaly from clinical examination and MCL>2 during the
2
time points of the study
Type of schistosomiasis
infection related variables at
baseline
Infected with S. haematobium
(Not infected with
S. haematobium)
0.356 (0.129 to 0.983)
p = 0.0461
1.105 (0.136 to 9.009) p = 0.9261 0.482 (0.253 to 0.919) p = 0.0271
Infected with S. mansoni (Not
infected with S. mansoni)
2.946 (1.267 to 6.848)
p = 0.0121
0.915 (0.235 to 3.562) p = 0.8991 1.479 (0.900 to 2.432) p = 0.1231
Estimates from model with dependent variable indicating the change of splenomegaly from clinical examination and MAL>2 during the
2 time points of the study
Type of schistosomiasis
infection related variables at
baseline
Infected with S. haematobium
(Not infected with
S. haematobium)
0.505 (0.155 to 1.647)
p = 0.2571
1.028 (0.125 to 8.474) p = 0.9791 0.487 (0.256 to 0.929) p = 0.0291
Infected with S. mansoni (Not
infected with S. mansoni)
4.353 (1.681 to 11.272)
p = 0.0021
0.953 (0.238 to 3.810) p = 0.9461 1.140 (0.681 to 1.908) p = 0.6191
Note: The comparison group for the dependent variable is ‘no pathology at both time points’
ORs, Odds Ratios; 95% CIs, 95% Confidence Intervals
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haematobium infections may have had active S. mansoni
infections in the past, particularly in such co-endemic
regions, which could account for the classic S. mansoni-
associated liver and splenic morbidity observed in S.
haematobium infected individuals. However, the
approximately matched ages of children between infec-
tion status groups sampled here may warrant against
this as a sufficient potential explanation, although we
admittedly cannot fully discount the possibility of some
very light current S. mansoni infections being missed
during the single Kato Katz examinations. An alternative
plausible explanation, therefore, may be related to the
fact that S. haematobium eggs are found in the liver and
do cause granulomas, albeit to a lesser extent than S.
mansoni, as both of these schistosome species involve a
hepatic portal system migration phase during their life-
cycles [32,33], which could plausibly result in some
pathology. In any case, further research into this poten-
tially very important observation, of liver pathology in S.
haematobium infections (urinary schistosomiasis), and
not only S. mansoni infections (intestinal schistosomia-
sis) is warranted.
As regards the bladder morbidity examined here, our
results indicated that at baseline children with single
and mixed schistosome species infections were signifi-
cantly more likely to have this risk. Moreover, the risk
of having such morbidity was greater in mixed infec-
tions than in single S. haematobium infections of the
same intensity. Once again the mechanisms behind such
increased bladder morbidity in mixed as compared to
single species infections is uncertain. As we predicted
from the results of the Cameroon study in humans
[5,6], combined with that know from laboratory mixed
species studies in mice [11], synergistic or antagonistic
interactions resulting from mixed species infections, and
in particular potential interspecific S. mansoni: S. hae-
matobium pairings, might be likely to lead to bladder
abnormalities as observed by US. In part, mixed species
infections within a single host may compete, and
increase their individual egg output and subsequent
virulence to their host, relative to that produced under
single species infections [34]. Indeed, it has been
observed in very high infection intensities cases, eggs
from either species can be found in a range of ‘addi-
tional’ internal organs [32], although the current ana-
lyses controlled for infection intensity and so this alone
is unlikely to fully explain the results here. More plausi-
bly the observed results may indicate S. haematobium
males mating with S. mansoni females and the subse-
quent (infertile) eggs produced from such couplings pas-
sing to the urinary oviposition site, thereby reducing the
amount of classical S. mansoni-induced morbidity whilst
increasing the classic S. haematobium-associated bladder
morbidity. Furthermore, it may be plausible that the
infertile, and immunogenically novel, hybrid eggs pro-
duced from such female S. mansoni and male S. haema-
tobium heterologous pairs in the urinary tract may not
be as adept at transversing the urinary tract wall, relative
to their pure-bred single species counterparts, and hence
may more frequently become trapped, and cause granu-
loma-related morbidity, in the urinary tract and bladder
tissues. Whatever the precise aetiology, the results indi-
cate again that any consideration of schistosome-asso-
ciated morbidity in the human hosts should examine
further than the traditional single species ‘liver/spleen’
for S. mansoni and bladder/urinary tract for S.
haematobium.
When pre- and post-MDA data were analyzed we
found that at baseline the highest prevalence of S. hae-
matobium infection was observed in Ségou while the
highest prevalences of S. mansoni infection and co-
infections were both found in Koulikoro. At follow-up,
prevalences of single and mixed S. haematobium infec-
tions significantly decreased with the exception of Kouli-
koro where prevalence of single S. haematobium
infections significantly increased. Furthermore, the pre-
valence of S. mansoni infection after PZQ treatment sig-
nificantly increased in all three areas in Mali, as has
been reported in Senegal and Egypt [8,9]. Heavy intensi-
ties for both S. haematobium and S. mansoni infections
have both significantly decreased in Koulikoro and
Segou after PZQ treatment. At follow-up there were sig-
nificant decreases in liver/spleen and bladder patholo-
gies in the Ségou area while in Bamako and Koulikoro
areas there were observed significant increases in blad-
der pathology. This finding does, as we predicted, high-
light the importance of looking at both liver and bladder
when assessing morbidity, particularly in areas of mixed
foci.
Moreover, multivariate analysis on the two years’ data
from Ségou area highlighted the causative role of S.
mansoni infections compared to absence of infection
with S. mansoni with respect to chronic liver morbidity,
both before and after PZQ treatment. More precisely,
we found that those children who were infected with S.
mansoni only compared to those uninfected at baseline
were significantly more likely to have liver morbidity at
follow-up. For those children who were infected with S.
haematobium only compared to those uninfected at
baseline, they were found significantly less likely to have
changes in their liver morbidity during the two years of
study. However, intensities of infection were not
included in this part of the analysis and further research
here is therefore warranted.
We do recognize the inherent limitations of this study,
where treatments provided could not be randomized
because of ethical reasons associated with a national
schistosomiasis control program, in addition to the a
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priori well-known focality of disease in the baseline
results of this study and the different number of treat-
ments delivered in each of the three study areas. Other
potentially confounding factors such as additional con-
current parasitic diseases, for example malaria, could
complicate the interpretation of results, and further
research to elucidate these complicating factors is war-
ranted. Nevertheless, we still believe that the results of
this study add important insights into polyparasite inter-
actions and their implications to the human host.
Conclusions
To conclude, this study found decreased liver morbidity
in mixed schistosome species infections compared to
single S. mansoni infections and increased bladder mor-
bidity in mixed schistosome species infections compared
to single S. haematobium infections. Single S. haemato-
bium or S. mansoni infections were also associated with
liver and spleen morbidity, while only single S. haemato-
bium infections were associated with bladder morbidity
in these children. PZQ treatment contributed to the
regression of some of the forms of such morbidities.
The precise biological mechanisms for these observa-
tions remain to be fully ascertained but, at least, the
estimates of schistosomiasis morbidity DALYs should
take the current findings into account.
Additional material
Additional file 1: Supplement for the manuscript ‘The impact of
single versus mixed schistosome species infections on liver, spleen
and bladder morbidity within Malian children pre and post
Praziquantel treatment’. This file contains some further statistical
analysis that supports the methodology finally used.
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